Financial Review: Bioanalytical Systems (BASI) vs. Its Peers

Share on StockTwits

Bioanalytical Systems (NASDAQ: BASI) is one of 39 public companies in the “Commercial physical research” industry, but how does it compare to its rivals? We will compare Bioanalytical Systems to similar businesses based on the strength of its institutional ownership, profitability, analyst recommendations, dividends, earnings, risk and valuation.


This table compares Bioanalytical Systems and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Bioanalytical Systems -7.75% -42.74% -6.38%
Bioanalytical Systems Competitors -56.00% -8.74% -4.50%

Analyst Ratings

This is a summary of recent recommendations for Bioanalytical Systems and its rivals, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Bioanalytical Systems 0 0 1 0 3.00
Bioanalytical Systems Competitors 231 1021 1892 92 2.57

Bioanalytical Systems presently has a consensus target price of $17.00, indicating a potential upside of 12.21%. As a group, “Commercial physical research” companies have a potential downside of 10.39%. Given Bioanalytical Systems’ stronger consensus rating and higher possible upside, research analysts clearly believe Bioanalytical Systems is more favorable than its rivals.

Valuation and Earnings

This table compares Bioanalytical Systems and its rivals revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Bioanalytical Systems $60.47 million -$4.68 million -43.29
Bioanalytical Systems Competitors $1.35 billion $64.04 million 7.90

Bioanalytical Systems’ rivals have higher revenue and earnings than Bioanalytical Systems. Bioanalytical Systems is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Insider and Institutional Ownership

10.6% of Bioanalytical Systems shares are owned by institutional investors. Comparatively, 42.0% of shares of all “Commercial physical research” companies are owned by institutional investors. 11.5% of Bioanalytical Systems shares are owned by company insiders. Comparatively, 15.7% of shares of all “Commercial physical research” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Volatility and Risk

Bioanalytical Systems has a beta of 1.92, meaning that its stock price is 92% more volatile than the S&P 500. Comparatively, Bioanalytical Systems’ rivals have a beta of 5.77, meaning that their average stock price is 477% more volatile than the S&P 500.


Bioanalytical Systems rivals beat Bioanalytical Systems on 9 of the 13 factors compared.

About Bioanalytical Systems

Bioanalytical Systems, Inc., doing business as Inotiv, provides drug discovery and development services to the pharmaceutical, chemical, and medical device industries; and sells analytical instruments to the pharmaceutical development and contract research industries in the United States, rest of North America, the Pacific Rim, Europe, and internationally. It operates through two segments, Contract Research Services and Research Products. The Contract Research Services segment offers screening and pharmacological testing, nonclinical safety testing, formulation development, regulatory compliance, and quality control testing services. This segment provides analytical method development and validation; drug metabolism, bioanalysis, and pharmacokinetics testing to identify and measure drug and metabolite concentrations in complex biological matrices; in vivo sampling services for the continuous monitoring of chemical changes in life; stability testing to ensure the integrity of various solutions used in nonclinical and clinical studies, and post-study analyses; non-clinical toxicology and pathology services; and climate-controlled archiving services for its customers' data and samples. The Research Products segment designs, develops, manufactures, and markets in vivo sampling systems and accessories, including disposables, training, and systems qualification; physiology monitoring tools; liquid chromatography and electrochemistry instruments platforms; analytical products comprising liquid chromatographic and electrochemical instruments with associated accessories; and in vivo sampling products consisting of Culex family of automated in vivo sampling and dosing instruments. Bioanalytical Systems, Inc. was founded in 1974 and is headquartered in West Lafayette, Indiana.

Receive News & Ratings for Bioanalytical Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioanalytical Systems and related companies with's FREE daily email newsletter.